The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity

Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448

(2018) Simeon Cua et al.   Oncotarget

Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein

(2017) Ariola Bardhi et al.   JOURNAL OF VIROLOGY

Modulating IgG effector function by Fc glycan engineering

(2017) Tiezheng Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity

(2017) Taia T. Wang et al.   SCIENCE

The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells

(2017) Pauline Estupina et al.   Oncotarget

FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality

(2016) Salina Louie et al.   BIOTECHNOLOGY AND BIOENGINEERING

Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity

(2016) Akiko Nagase-Zembutsu et al.   CANCER SCIENCE

Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice

(2016) Sandra Gallagher et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Antibodies to watch in 2017

(2016) Janice M. Reichert   mAbs

XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer

(2016) Juergen M. Schanzer et al.   mAbs

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells

(2016) Katharine D. Grugan et al.   mAbs

Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies

(2016) Marco Thomann et al.   MOLECULAR IMMUNOLOGY

Broadly Neutralizing Antibodies for HIV Eradication

(2016) Kathryn E. Stephenson et al.   Current HIV/AIDS Reports

Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks

(2015) Azizul Haque et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Inactivation of GDP-fucose transporter gene (Slc35c1) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies

(2015) Kah Fai Chan et al.   Biotechnology Journal

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

(2015) M. Duvic et al.   BLOOD

In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris

(2015) Sujatha Gomathinayagam et al.   JOURNAL OF BIOTECHNOLOGY

A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options

(2015) Florian Eisner et al.   JOURNAL OF CLINICAL PATHOLOGY

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

(2015) V Goede et al.   LEUKEMIA

Antibodies to watch in 2016

(2015) Janice M. Reichert   mAbs

Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies

(2015) Tamir Dingjan et al.   MOLECULAR IMMUNOLOGY

A common glycan structure on immunoglobulin G for enhancement of effector functions

(2015) Chin-Wei Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inactivation of GDP-fucose transporter gene (Slc35c1) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies

(2015) Kah Fai Chan et al.   Biotechnology Journal

In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity

(2015) Marco Thomann et al.   PLoS One

Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants

(2015) Tetyana Dashivets et al.   PLoS One

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

(2014) G. Cartron et al.   BLOOD

Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment

(2014) M. E. Vail et al.   CANCER RESEARCH

A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties

(2014) Juergen M. Schanzer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

(2014) Caroline S Breton et al.   Journal of Hematology & Oncology

Antibodies to watch in 2015

(2014) Janice M Reichert   mAbs

The therapeutic monoclonal antibody market

(2014) Dawn M Ecker et al.   mAbs

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy

(2014) A. Hiatt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aiming at the sweet side of cancer: Aberrant glycosylation as possible target for personalized-medicine

(2013) Vered Padler-Karavani   CANCER LETTERS

RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation

(2013) C. Mirschberger et al.   CANCER RESEARCH

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity

(2013) Margaret E. Ackerman et al.   JOURNAL OF CLINICAL INVESTIGATION

Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Gilles A. Salles et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Franck Andre Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies

(2013) K Matlawska-Wasowska et al.   LEUKEMIA

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

(2013) Karen Silence et al.   mAbs

Roles of the nucleotide sugar transporters (SLC35 family) in health and disease

(2013) Zhiwei Song   MOLECULAR ASPECTS OF MEDICINE

Development of orally active inhibitors of protein and cellular fucosylation

(2013) N. M. Okeley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression of the carcinoma markers: the sialylated Lewis A and X carbohydrate antigens in normal laryngeal surface epithelium and submucosal glands from old humans

(2012) Svend Kirkeby et al.   APMIS

IgG-Fc glycoengineering in non-mammalian expression hosts

(2012) Andreas Loos et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

(2012) G. Salles et al.   BLOOD

GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab

(2012) C. A. Gerdes et al.   CLINICAL CANCER RESEARCH

Glycans as targets for therapeutic antitumor antibodies

(2012) Catherine Rabu et al.   Future Oncology

Identification of functional elements of the GDP-fucose transporter SLC35C1 using a novel Chinese hamster ovary mutant

(2012) Peiqing Zhang et al.   GLYCOBIOLOGY

Marketing approval of mogamulizumab

(2012) Alain Beck et al.   mAbs

An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab

(2012) John R. Gasdaska et al.   MOLECULAR IMMUNOLOGY

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism

(2011) S. Veeramani et al.   BLOOD

A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo

(2011) Elizabeth Ward et al.   BRITISH JOURNAL OF HAEMATOLOGY

High Throughput Isolation and Glycosylation Analysis of IgG–Variability and Heritability of the IgG Glycome in Three Isolated Human Populations

(2011) Maja Pučić et al.   MOLECULAR & CELLULAR PROTEOMICS

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

(2011) S. Dalle et al.   MOLECULAR CANCER THERAPEUTICS

The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line

(2011) Xun Xu et al.   NATURE BIOTECHNOLOGY

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

(2011) L. Zeitlin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

(2011) C. Ferrara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies

(2010) Laetitia Malphettes et al.   BIOTECHNOLOGY AND BIOENGINEERING

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

(2010) Teemu T. Junttila et al.   CANCER RESEARCH

Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma

(2010) T. Ishii et al.   CLINICAL CANCER RESEARCH

Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase

(2010) H. H. von Horsten et al.   GLYCOBIOLOGY

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody

(2010) R. Herbst et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Ebola haemorrhagic fever

(2010) Heinz Feldmann et al.   LANCET

Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding

(2010) Damian Houde et al.   MOLECULAR & CELLULAR PROTEOMICS

A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies

(2009) Pina M. Cardarelli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Improved Virus Neutralization by Plant-produced Anti-HIV Antibodies with a Homogeneous β1,4-GalactosylatedN-Glycan Profile

(2009) Richard Strasser et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Defucosylated Anti-CCR4 Monoclonal Antibody Exerts Potent ADCC against Primary ATLL Cells Mediated by Autologous Human Immune Cells in NOD/Shi-scid, IL-2R null Mice In Vivo

(2009) A. Ito et al.   JOURNAL OF IMMUNOLOGY

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulated Glycosylation Patterns of IgG during Alloimmune Responses against Human Platelet Antigens

(2008) Manfred Wuhrer et al.   JOURNAL OF PROTEOME RESEARCH

Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure

(2008) Richard Strasser et al.   PLANT BIOTECHNOLOGY JOURNAL